Search

Your search keyword '"Matsumoto, Hirotaka"' showing total 36 results

Search Constraints

Start Over You searched for: Author "Matsumoto, Hirotaka" Remove constraint Author: "Matsumoto, Hirotaka" Publisher elsevier bv Remove constraint Publisher: elsevier bv
36 results on '"Matsumoto, Hirotaka"'

Search Results

1. Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP)

3. MO3-6 The elderly subgroup analysis in real world survey (CRIMSON) of concurrent chemoradiotherapy in locally advanced NSCLC

5. MO57-4 Association of Glasgow prognostic score with efficacy and safety of first-line osimertinib in EGFR mutated NSCLC (OSI-FACT exploratory analysis)

6. Alternating Therapy With Osimertinib and Afatinib Blockades EGFR Secondary Mutation in EGFR-Mutant Lung Cancer: A Single-Arm Phase II Trial

8. Safety and efficacy of osimertinib rechallenge or continuation after pneumonitis: A multicentre retrospective cohort study

9. Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer

10. Prospective multicenter cohort study of durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis

11. First-Line Pembrolizumab Monotherapy for Advanced NSCLC With Programmed Death-Ligand 1 Expression Greater Than or Equal to 50%: Real-World Study Including Older Patients in Japan

12. Histologic transformation of epidermal growth factor receptor–mutated lung cancer

13. A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC

14. Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation–positive non–small-cell lung cancer in a real-world setting (OSI-FACT)

15. Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMSON)

17. Association Between Early Immune-related Adverse Events and Clinical Outcomes in Patients With Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors

21. Different origins of lysophospholipid mediators between coronary and peripheral arteries in acute coronary syndrome

22. Altered Cortical Dynamics and Cognitive Function upon Haploinsufficiency of the Autism-Linked Excitatory Synaptic Suppressor MDGA2

23. Blood levels of serotonin are specifically correlated with plasma lysophosphatidylserine among the glycero-lysophospholipids

27. Genotoxic potential and in vitro tumour-promoting potential of 2-dodecylcyclobutanone and 2-tetradecylcyclobutanone, two radiolytic products of fatty acids

32. Evaluation of a liver micronucleus assay in young rats (IV): A study using a double-dosing/single-sampling method by the Collaborative Study Group for the Micronucleus Test (CSGMT)/Japanese Environmental Mutagen Society (JEMS)–Mammalian Mutagenicity Study Group (MMS)

33. Evaluation of a liver micronucleus assay in young rats (III): A study using nine hepatotoxicants by the Collaborative Study Group for the Micronucleus Test (CSGMT)/Japanese Environmental Mutagen Society (JEMS)–Mammalian Mutagenicity Study Group (MMS)

Catalog

Books, media, physical & digital resources